Isolated central hypothyroidism, characterized by insufficient TSH secretion resulting in low levels of thyroid hormones, is a rare disorder. We report a boy in whom isolated central hypothyroidism was diagnosed at 9 yr of age. Complete absence of TSH and PRL responses to TRH led us to speculate that he had an inactivating mutation of the TRH receptor gene. The patients' genomic DNA was isolated, and the entire coding region of the TRH receptor was amplified by the PCR and sequenced directly. Confirmation of the mutations and haplotyping of the family was performed using restriction enzymes. The biological activity of the wild-type and mutated TRH receptors was verified by evaluating the binding of labeled TRH and stimulation by TRH of total inositol phosphate accumulation in transfected HEK-293 and COS-1 cells. The patient was found to be a compound heterozygote, having inherited a different mutated allele from each of the parents; both mutations were in the 5Ј-part of the gene. Mutated receptors were unable to bind TRH and to activate total inositol phosphate accumulation. Our report is the first description of naturally occurring inactivating mutations of a G protein-coupled receptor linked to the phospholipase C second messenger pathway. The prevalence and phenotypic spectrum of TRH receptor mutations in isolated central hypothyroidism remain to be established. (J Clin Endocrinol Metab 82: 1361-1365, 1997) C ENTRAL hypothyroidism, characterized by insufficient TSH secretion resulting in low levels of thyroid hormones, is a rare disorder with an estimated frequency of 0.005% in the general population; most cases are associated with other pituitary deficiencies and are due to tumors or infiltrative diseases of the hypothalamic-pituitary area or to pituitary atrophy (1). Isolated central hypothyroidism due to mutations of the TSH ␤-subunit has been described (2, 3). On the other hand, inactivating mutations of receptors for hypothalamic hormones can also lead to pituitary hormone deficiencies, as recently reported for the GHRH receptor (4).
C ENTRAL hypothyroidism, characterized by insufficient TSH secretion resulting in low levels of thyroid hormones, is a rare disorder with an estimated frequency of 0.005% in the general population; most cases are associated with other pituitary deficiencies and are due to tumors or infiltrative diseases of the hypothalamic-pituitary area or to pituitary atrophy (1) . Isolated central hypothyroidism due to mutations of the TSH ␤-subunit has been described (2, 3) . On the other hand, inactivating mutations of receptors for hypothalamic hormones can also lead to pituitary hormone deficiencies, as recently reported for the GHRH receptor (4) .
We report a patient with central hypothyroidism whose plasma TSH and PRL levels did not rise after the administration of TRH. He was found to be a compound heterozygote, having inherited from each parent a different mutation in the TRH receptor gene. Both mutations resulted in a receptor with reduced or absent biological activity.
Case Report
The propositus, the second of three sons born to nonconsanguineous Caucasian parents, was referred for evaluation of short stature at 8.9 yr of age. His clinical history was unremarkable except for poor school performance. On examination, his height was 115.2 cm (Ϫ2.6 sd), his weight was 23.0 kg (Ϫ0.4 sd), and his heart rate was 64 beats/min without other signs of hypothyroidism. The bone age was 4 yr (Ϫ4.1 sd). Plasma T 4 was 4.0 g/dL (52 nmol/L; normal, 4.5-11.5 g/dL), and TSH was 1.3 mU/L (normal, 0.1-5.0). A retrospective verification of T 4 and TSH values obtained at neonatal screening revealed that the T 4 value, at 4.9 g/dL (64 nmol/L), was abnormally low (normal, Ͼ6.7 g/dL), but the TSH concentration was normal (13 mU/L; normal, Ͻ15 mU/L). Because of the normal TSH value, the patient had not been recalled. The peak plasma GH reponses to clonidine and levodopa were 31.8 and 15.6 g/L, respectively (normal, Ͼ8). Baseline plasma PRL was 6.2 g/L (normal, Ͻ15), and iv TRH failed to induce a rise in either TSH or PRL levels. On a computerized tomographic scan, the pituitary volume was normal at 175 mm 3 (5); on films of the abdomen, taken after the scan, a stippled right femoral epiphysis was noted. A diagnosis of central hypothyroidism of unknown cause was made. The patient was started on T 4 at a daily dose of 50 g. Normalization of plasma T 4 levels (9.3 g/dL or 119 nmol/L) was associated with an increase in heart rate (to 100 beats/min) and a slight and transient increase in height velocity (from 4.8 to 7.3 cm/yr). At 10.9 yr, height velocity decreased again to 2.7 cm/yr, although the compliance was good, and the dose of T 4 was increased to 75 g/day. When the patient was 12.3 yr old, it was decided to repeat the TRH test after 1 month of T 4 withdrawal, to confirm the pituitary unresponsiveness to the peptide, and to compare it to the response of the other family members who had normal thyroid function tests. The patient's baseline plasma T 4 was 3.3 g/dL (42 nmol/L), and TSH was 2.2 mU/L; iv TRH failed again to release TSH and PRL, whereas all of the other family members had a normal response to the peptide (Fig. 1) . At 11.9 yr, the patient's overall intellectual quotient (I.Q.) was deter-mined, by the Wechsler Intelligence Scale for Children (revised) (6) , to be 92 (verbal, 79; Performance, 109). The testicular volume started to increase at 12.5 yr, with normal pubertal progression thereafter. The two brothers and the parents had no signs or symptoms of hypothyroidism. The overall I.Q. of the elder brother at age 16 yr was 76 (verbal, 74; performance, 81), and that of the younger brother at age 11 yr was 89 (verbal, 86; performance, 93). Although the parents did not undergo formal I.Q. testing, they appeared to be of normal intelligence, but their educational level was low.
Materials and Methods

Tests of thyroid function
Plasma T 4 and TSH were measured on the AutoDelfia by timeresolved immunofluorometric assays (Wallac, Vaudreuil, Canada). PRL was measured by RIA (Intermedico, Markham, Canada). The TRH test was performed as previously reported (7, 8) , using 7 g/kg (maximum, 200 g) Relefact (Hoechst-Roussel Canada, Montreal, Canada).
Preparation of genomic DNA and DNA sequencing
Genomic DNA was isolated from peripheral blood cells as previously described (9) . For sequencing, the entire coding region of the TRH receptor gene was subdivided into four overlapping segments (no. 1-4 in a 5Ј-3Ј direction). DNA was amplified by the PCR as previously described (9), using sets of primers obtained from Dr. Q. H. Dong (Molecular Pathophysiology Branch, NIH/NIDDK, Bethesda, MD) for segments 1, 2, and 4. For segment 3, which contains the intron, customized primers were synthesized and used to amplify the intron-exon boundaries of this part of the TRH receptor gene (10) . Direct sequencing was performed as previously described (11) 
Confirmation of the mutations and haplotyping
The creation of new restriction sites by each of the two mutations was used to confirm the presence of the mutations and to identify family members as carriers of the mutated alleles. PCR was performed under the same conditions as previously described (9), except for the addition of [
32 P]deoxy-ATP. After amplification of genomic DNA of each family member, the PCR products were digested with the appropriate enzymes and electrophoresed on a polyacrylamide gel. The gel was dried and exposed overnight to an x-ray film. The appearance of additional digested fragments indicated the presence of a mutation in one of the two alleles.
Construction of wild-type and mutant TRH receptor complementary DNA (cDNA) expression vectors
The full-length, wild-type TRH receptor cDNA was synthesized by reverse transcription of TRH receptor messenger ribonucleic acid extracted from a normal human pituitary gland obtained at autopsy. The cDNA was cloned (9) into pcDNA3 (Invitrogen Corp., San Diego, CA). Segment 1 of the patient's TRH receptor gene was cloned in pBluescript KS ϩ (Stratagene, La Jolla, CA). More than three clones of each allele were verified by sequencing with Sequenase kit 2.0 (U.S. Biochemical Corp., Cleveland, OH). Mutant TRH receptors (maternally derived, designated M-Stop and paternally derived, designated F-TM3) were constructed by removing the mutated segment 1 and using it to replace the normal segment 1 of the wild-type receptor in pcDNA3. The entire sequence of the cloned receptors was verified and was identical to that of the published TRH receptor (12, 13) , except for the expected mutations in the mutant clones. 
Functional studies of the TRH receptors in a transient expression system
HEK-293 and COS-1 cells were maintained in DMEM (Sigma Chemical Co., Dorset, UK) containing 10% heat-inactivated FCS at 37 C and 5% carbon dioxide. Monolayer cultures of either HEK-293 or COS-1 cells (1.2 ϫ 10 6 cells/well) were transiently transfected with either the wildtype or the mutant human TRH receptor cDNAs cloned in pcDNA3 (5 g/well) using Transfectam (Promega, Southampton, UK). The efficiency of the method of DNA transfection has been verified by cotransfecting the cells with a plasmid containing the gene for ␤-galactosidase and assaying the enzyme activity in cell extracts using a commercial kit (Promega).
Radioligand binding assays were performed as previously reported (12) 
For studies of inositol phosphate accumulation, normal DMEM was replaced with inositol-free DMEM containing myo- [2- 3 H]inositol (Amersham, Aylesbury, UK) 24 h after transfection. This medium was removed 48 h later, and the cells were incubated for 20 min in phosphatebuffered saline containing 10 mmol/L lithium chloride and various concentrations of TRH. Tritium-labeled total inositol phosphates were then extracted, separated using an anion exchange resin, and assayed by liquid scintillation counting (12) .
Results
DNA sequencing and haplotyping
Several germ-line mutations were found only in segment 1 of the patient's DNA. Sequencing of 10 clones of segment 1 further indicated that the mutations were in different alleles, as shown in Fig. 2 . In one allele, a cytosine to thymine (C to T) mutation at position 49 resulted in arginine (CGA) being substituted by a premature stop codon (TGA) at peptide position 17. In the other allele, a deletion of nine nucleotides from position 343 to 351 plus a mutation of guanine to adenine (G to A) at position 352 were found. The deletion resulted in the loss of three amino acid residues (Ser 115 , Ile 116 , and Thr 117 ) at the cytoplasmic end of the third transmembrane domain of the receptor. The mutation at position 352 resulted in the replacement of alanine (GCC) by threonine (ACC) at peptide position 118 (Fig. 2) . The presence of different mutations in each of the patient's alleles indicated that he is a compound heterozygote. The mutation at position 49 generated a new restriction site for the enzyme NlaIII, whereas the deletion plus mutation at positions 343-352 created a new restriction site for the enzyme RsaI. Family studies applying restriction site enzymatic digestion to the respective parts of the gene traced each of the mutant alleles to either one of the parents (Fig. 3) and provided evidence that the elder brother of the patient had also inherited the mother's mutant allele. The heterozygous state of each parent and that of the elder brother were confirmed by the presence of , and Thr 117 amino acid residues and the mutation GCC3 ACC resulted in the substitution of alanine by threonine at position 118. In the maternal allele, the mutation CGA3 TGA resulted in a premature stop codon instead of arginine at position 17. The substituted nucleotides are outlined in black.
one normal allele (Fig. 3) . These results indicate that the patient and his elder brother had inherited germ-line mutations. No other mutations were found by direct sequencing of segments 2, 3 and 4 of the patient's DNA. Figure 4 (left panel) shows radioligand displacement curves with [3Me-His 2 ]TRH and membranes prepared from HEK-293 cells expressing wild-type and mutant human TRH receptors. The wild-type receptor exhibited high affinity binding with an ED 50 of approximately 1.6 nmol/L. In contrast, the maternally derived mutant (M-Stop) showed no measurable binding, whereas the paternally derived mutant (F-TM 3) showed a very small amount of binding. Untransfected HEK-293 cells did not demonstrate any binding (results not shown). The dose-response curve of TRH-induced increase in total inositol phosphate production in COS-1 cells expressing either the wild-type or the mutant receptor is also shown in Fig. 4 (right panel) . The EC 50 value of total inositol phosphate stimulation by TRH for COS-1 cells expressing the wild-type receptor was 2.4 nmol/L. COS-1 cells expressing either one of the two mutant receptors showed no stimulation of total inositol phosphate production in response to increasing concentrations of TRH. Similarly, untransfected or sham-transfected COS-1 cells demonstrated no inositol phosphate response at any of the TRH doses used.
Functional studies
Discussion
The TRH receptor is a member of the large family of G protein-coupled, seven-transmembrane domain type of peptide receptors (14) . The human TRH receptor has recently been cloned, and its structure and functionality have been found to be similar to those of the rat and mouse receptor (10, 12, 13) . Receptor-mediated stimulation of the synthesis and release of TSH and PRL is exerted through activation of the inositol phosphate-calcium-protein kinase C transduction pathway (15) . The third transmembrane helix is an essential constituent of the TRH receptor binding pocket (16) . The results obtained in our patient show that his TRH receptor is severely altered. Indeed, the presence of a stop codon at amino acid position 17 in the mutated maternal allele presumably results in a truncated protein, missing all seven transmembrane domains. On the other hand, deletion of three amino acids and substitution of alanine by threonine in the mutated paternal allele presumably alters the tertiary structure of the third transmembrane helix. Both mutated receptors, when transfected in eukaryotic cells, resulted in greatly reduced or absent TRH binding and TRH stimulation of inositol phosphate accumulation; this confirms their role in the pathophysiology of our patient's central hypothyroidism. Although naturally occurring activating or inactivating mutations of G protein-coupled receptors linked to other intracellular signaling systems have been reported (17) , to our knowledge ours is the first description of naturally occurring inactivating mutations of a G protein-coupled receptor linked to the phospholipase C second messenger pathway.
Central hypothyroidism, defined as low plasma total and free T 4 concentrations in the presence of normal TSH values, is rare. It may result from either hypothalamic or pituitary lesions and usually occurs in association with other pituitary hormone deficiencies (1) . The clinical manifestations of central hypothyroidism are usually mild, especially when it is isolated (1). Indeed, in our patient, the only presenting symptoms were short stature with markedly delayed bone maturation, which shows the exquisite sensitivity of these markers of hypothyroidism in children (18) . It is uncertain whether the TRH-R gene defect is causally related to our patient's cognitive deficiencies, as his two unaffected brothers had similar learning difficulties and subnormal I.Q.; however, we suspect that these problems may be related to the low socioeducational status of the family.
Extrapituitary expression of the TRH receptor has been reported, suggesting that TRH may have nonendocrine functions (19) . However, our patient's phenotype, characterized only by isolated central hypothyroidism, indicates that endogenous TRH does not appear to play a major physiological FIG. 3 . Confirmation of the mutations in the TRH receptor gene in family members. Genomic DNA from peripheral leukocytes was amplified by PCR using the sense primer 5Ј-GGC TCA CCA GGT AGC AGT TTG T-3Ј and the antisense primer 5Ј-TGA GGC TGG CAG TAG CTG ATC T-3Ј. The presence of thymidine at position 49 produces an additional NlaIII restriction site, whereas the deletion of nucleotides 343-351 plus the presence of adenine at position 352 creates an additional NlaI restriction site. The upper gel shows that all family members have either two alleles (father and one son) or one allele (mother and two sons) that are normally digested with NlaIII, creating a 139-bp fragment (Nla 1) and three smaller fragments (not shown). It also shows that the mother and two sons (the propositus and the elder son) all have a mutant allele containing a new restriction site that, when digested with NlaIII, cuts the 139-bp fragment in two DNA fragments of 85 and 54 bp (Nla 2). The lower gel shows that all family members have either two alleles (mother and two sons) or one allele (father and the propositus) that are normally digested with RsaI, creating a fragment of 220 bp and another of 177 bp (RsaI); it also shows that the father and the propositus have a mutant allele containing a new restriction site that, when digested with RsaI, cuts the 177-bp fragment to produce a DNA fragment of 149 bp (Rsa 2) and a smaller fragment (not shown). The pedigree above the gels shows the pattern of inheritance of the mutant TRH receptor alleles. u, Undigested; d, digested.
